AR077214A1 - Heterociclos nitrogenados y composiciones farmaceuticas que los contienen - Google Patents

Heterociclos nitrogenados y composiciones farmaceuticas que los contienen

Info

Publication number
AR077214A1
AR077214A1 ARP100102226A ARP100102226A AR077214A1 AR 077214 A1 AR077214 A1 AR 077214A1 AR P100102226 A ARP100102226 A AR P100102226A AR P100102226 A ARP100102226 A AR P100102226A AR 077214 A1 AR077214 A1 AR 077214A1
Authority
AR
Argentina
Prior art keywords
alkyl
ralk
independently
heterocycle
aryl
Prior art date
Application number
ARP100102226A
Other languages
English (en)
Inventor
Joe A Tran
Chen Chen
Original Assignee
Neurocrine Biosciences Inc
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc, Boehringer Ingelheim Int filed Critical Neurocrine Biosciences Inc
Publication of AR077214A1 publication Critical patent/AR077214A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

Compuestos para el tratamiento de varias afecciones relacionadas con el metabolismo en un paciente. También composiciones que contienen un compuesto en combinacion con un portador farmacéuticamente aceptable, así como métodos relacionados con su uso en un paciente que lo necesita. Reivindicacion 1: Un compuesto de la formula (1) en donde: X1, X2, X3 y X4 son, independientemente, -N- o -C(R5)-; Y1 e Y2 son, independientemente, -N- o -C(R3)-; A es -O- o -N(R7)-; R1 es RAlk, aril-alquilo C1-4, heterociclo-alquilo C1-4, -C(=O)R7, -CO2R6, -SO2R6, -C(=O)N(R7)2, -C(=S)N(R7)2, arilo o heterociclo, en donde cada Ralk, alquilo, arilo y heterociclo se sustituyen opcionalmente con 1 - 4 sustituyentes que se seleccionan, independientemente entre sí, de R9; R2, en cada caso, es independientemente alquilo C1-4, F, hidroxi o alquil C1-4-O-; R3, en cada caso, es independientemente H, halogeno, CN, alquilo C1-4, alquil C1-4-O- o alquil C1-4-S-; R4, en cada caso, es independientemente H, halogeno o alquilo C1-4; R5, en cada caso, es independientemente H, halogeno, ciano, hidroxi, RAlk, haloalquilo C1-4, -NO2, -C(O)R6, -CO2R6, -C(=O)N(R7)2, -SO2N(R7)2, -S(=O)R6, -S(=O)2R6, alquil C1-6-O-, haloalquil C1-4-O-, -N(R7)2, alquil C1-6-S-, arilo, aril-alquilo C1-6, heterociclo, heterociclo-alquilo C1-6, -NR7C(=O)R6, -NR7C(=O)N(R7)2, -NR7C(=O)OR7, -NR7C(=NR7)N(R7)2 o -NR7S(=O)2N(R7)2, en donde cada RAlk, alquilo, arilo y heterociclo se sustituyen, opcionalmente, con 1 - 5 sustituyentes que se seleccionan, independientemente entre sí, de R9; R6 es RAlk, heterociclo, heterociclo-alquilo C1-3 o arilo, en donde cada RAlk, alquilo, heterociclo y arilo se sustituyen, opcionalmente, con 1 - 4 sustituyentes que se seleccionan, independientemente entre sí, de R9; R7, en cada caso, es independientemente H o RAlk, en donde cada RAlk se sustituye, opcionalmente, con 1 - 4 sustituyentes que se seleccionan, independientemente entre sí, de halogeno, hidroxi, -N(R8)2, alquil C1-4-O- y -CO2R8; R8, en cada caso, es independientemente H o alquilo C1-4; R9, en cada caso, es independientemente ciano, hidroxi, RAlk, arilo, aril-alquilo C1-3, heterociclo, halogeno, oxo, haloalquilo C1-4, -NO2, -C(=O)H, -CO2R8, -OC(=O)RAlk, -C(=O)N(R7)2, -SO2N(R7)2, -S(=O)RAlk, S(=O)2RAlk, alcoxi C1-6, haloalcoxi C1-4, -N(R7)2, -SR7, -NR7C(=O)RAlk, -NR7C(=O)ORAlk o -NR7C(=O)N(R7)2, en donde cada RAlk, alquilo, arilo y heterociclo se sustituyen, opcionalmente, con 1 - 4 sustituyentes que se seleccionan, independientemente entre sí, de halogeno, hidroxi, -N(R8)2, alquil C1-4-O-, -NR7CO2R7, -NR7SO2R7 y -CO2R8; RAlk, en cada caso, es independientemente alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-3, cicloalquenilo C4-8 o cicloalquenil C4-8-alquilo C1-3; m es 0, 1 o 2; n es 0, 1 o 2; p es 0 o 1; y q es 0, 1 o 2, incluso cualquier tautomero y estereoisomero de aquel, o una sal de aquel, o un solvato o hidrato de aquel.
ARP100102226A 2009-06-24 2010-06-23 Heterociclos nitrogenados y composiciones farmaceuticas que los contienen AR077214A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22012509P 2009-06-24 2009-06-24

Publications (1)

Publication Number Publication Date
AR077214A1 true AR077214A1 (es) 2011-08-10

Family

ID=42712012

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102226A AR077214A1 (es) 2009-06-24 2010-06-23 Heterociclos nitrogenados y composiciones farmaceuticas que los contienen

Country Status (6)

Country Link
US (1) US8481731B2 (es)
EP (1) EP2445901A1 (es)
JP (1) JP2012530758A (es)
AR (1) AR077214A1 (es)
TW (1) TW201113269A (es)
WO (1) WO2010149685A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410089B2 (en) * 2009-02-18 2013-04-02 Takeda Pharmaceutical Company Limited Fused heterocyclic ring compound
AU2010264720A1 (en) 2009-06-24 2011-12-08 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
WO2010149685A1 (en) 2009-06-24 2010-12-29 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
EP2532656A1 (en) 2010-02-01 2012-12-12 Nippon Chemiphar Co., Ltd. Gpr119 agonist
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
EP2643311A1 (en) 2010-11-26 2013-10-02 Lupin Limited Bicyclic gpr119 modulators
UY33805A (es) 2010-12-17 2012-07-31 Boehringer Ingelheim Int ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?.
WO2012098217A1 (en) 2011-01-21 2012-07-26 Boehringer Ingelheim International Gmbh Fused dihydrofurans as gpr119 modulators for the treatment of diabetes, obesity and related disorders
JP5935154B2 (ja) 2011-03-14 2016-06-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｐｒ１１９モジュレーターとしてのｎ−シクロプロピル−ｎ−ピペリジニルベンズアミド
JP6094578B2 (ja) 2011-06-09 2017-03-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝性障害の治療のためのｇｐｒ１１９モジュレーターとしての置換ピペリジン
ES2784316T3 (es) * 2015-04-29 2020-09-24 Arena Pharm Inc 1-Heteroaril-indolin-4-carboxamidas como moduladores de GPR52 útiles para el tratamiento o la prevención de trastornos relacionados con el mismo
TWI682707B (zh) * 2017-02-24 2020-01-11 緯創資通股份有限公司 組裝組件及其組裝方法

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
US20030017528A1 (en) * 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
US6221660B1 (en) * 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
US20040171630A1 (en) 2001-06-19 2004-09-02 Yuntae Kim Tyrosine kinase inhibitors
DE10225574A1 (de) 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
WO2004043925A2 (en) 2002-11-08 2004-05-27 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
DK1599468T3 (da) 2003-01-14 2008-02-04 Arena Pharm Inc 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi
US7083933B1 (en) * 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
EP1711491A1 (en) 2003-12-24 2006-10-18 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
DK1756084T3 (da) 2004-06-04 2009-03-23 Arena Pharm Inc Substituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser beslægtet dermed
US20080312281A1 (en) 2004-12-24 2008-12-18 Matthew Colin Thor Fyfe G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes
US8193359B2 (en) 2004-12-24 2012-06-05 Prosidion Limited G-protein coupled receptor agonists
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
JP2008527030A (ja) 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なインドール類
WO2006077365A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
JP2008527027A (ja) 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なインドール類
NZ564759A (en) 2005-06-30 2011-08-26 Prosidion Ltd GPCR agonists
MX2007016545A (es) 2005-06-30 2008-02-21 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
EP1907383A1 (en) 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
EP1907384A2 (en) 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
CN101263135A (zh) 2005-09-16 2008-09-10 艾尼纳制药公司 代谢调节剂和代谢相关病症的治疗
BRPI0710181A2 (pt) 2006-03-16 2011-08-09 Novartis Ag compostos orgánicos
BRPI0710839A2 (pt) 2006-04-06 2011-08-23 Prosidion Ltd agonistas heterocìclicos de gpcr
CL2007001011A1 (es) 2006-04-11 2008-05-16 Arena Pharm Inc Metodo para la identificacion de secretagogos de gip, polipeptido inhibidor gastrico; y uso de un receptor acoplado a proteina g para clasificar compuestos de prueba como secretagogos de gip.
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
GB0610746D0 (en) * 2006-06-01 2006-07-12 Prosidion Ltd Method of treatment
TW200811140A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811147A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
WO2008008887A2 (en) * 2006-07-13 2008-01-17 Smithkline Beecham Corporation Gpr119 agonists for treating metabolic disorders
WO2008009924A2 (en) 2006-07-18 2008-01-24 Biolipox Ab Indoles useful in the treatment of inflammation
WO2008025799A1 (en) 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Pyridazine compounds for treating gpr119 related disorders
CN101657471B (zh) 2006-12-06 2013-07-03 史密丝克莱恩比彻姆公司 二环化合物及其作为抗糖尿病药的用途
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
AR064736A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr
EA016507B1 (ru) 2007-01-04 2012-05-30 Прозидион Лимитед Пиперидиновые агонисты gpcr
PE20081659A1 (es) 2007-01-04 2008-10-24 Prosidion Ltd Agonistas de gpcr
ATE523507T1 (de) 2007-01-04 2011-09-15 Prosidion Ltd Piperidin-gpcr-agonisten
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
TW200848054A (en) * 2007-02-28 2008-12-16 Eisai R&D Man Co Ltd Two cyclic oxomorpholine derivatives
ATE482209T1 (de) 2007-03-08 2010-10-15 Irm Llc Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität
JP5164972B2 (ja) 2007-03-29 2013-03-21 第一三共株式会社 ｃＰＬＡ２阻害活性を有するインドール誘導体およびその用途並びに製造方法
PE20090222A1 (es) 2007-05-04 2009-03-27 Bristol Myers Squibb Co Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119
ES2388315T3 (es) 2007-05-04 2012-10-11 Bristol-Myers Squibb Company Agonistas [6,5]-bicíclicos de receptores GPR119 acoplados a la proteína G
PE20090449A1 (es) 2007-07-17 2009-04-18 Bristol Myers Squibb Co Agonistas de receptor acoplado a proteina g gpr119 de piridona
KR20100033419A (ko) 2007-07-19 2010-03-29 메타볼렉스, 인코포레이티드 당뇨병 및 대사 장애의 치료를 위한 ｒｕｐ3 또는 ｇｐｒ119 수용체의 작용제로서 ｎ-아자시클릭 치환된 피롤, 피라졸, 이미다졸, 트리아졸 및 테트라졸 유도체
EP2200609A1 (en) 2007-09-10 2010-06-30 Prosidion Limited Compounds for the treatment of metabolic disorders
BRPI0817211A2 (pt) 2007-09-20 2017-05-16 Irm Llc composto composições como moduladores da atividade de gpr119
KR101536021B1 (ko) * 2007-10-16 2015-07-10 다이이찌 산쿄 가부시키가이샤 피리미딜 인돌린 화합물
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
CN101910151A (zh) 2007-10-22 2010-12-08 先灵公司 双环杂环衍生物及其作为gpr119活性调节剂的用途
US20100261743A1 (en) 2007-12-06 2010-10-14 Glaxosmithkline Llc Novel seh inhibitors and their use
BRPI0907584A2 (pt) 2008-02-22 2015-07-21 Irm Llc Composto e composições como moduladores de atividade de gpr119
AU2009217361A1 (en) 2008-02-22 2009-08-27 Irm Llc Compounds and compositions as modulators of GPR119 activity
WO2009106561A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Pyrazine compounds for treating gpr119 related disorders
WO2009106565A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Agonists of gpr119
JP5369093B2 (ja) 2008-03-31 2013-12-18 全薬工業株式会社 細胞保護作用を有するピリミジン誘導体およびその用途
BRPI0909469A2 (pt) 2008-03-31 2015-12-29 Metabolex Inc compostos de oximetileno de arila e usos dos mesmos
JP2011516557A (ja) 2008-04-07 2011-05-26 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性のモジュレーターとしての化合物および組成物
WO2009125434A2 (en) 2008-04-07 2009-10-15 Cadila Healthcare Limited Oxime derivatives
EP2297129B1 (en) 2008-04-14 2013-07-24 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
WO2009150144A1 (en) 2008-06-10 2009-12-17 Inovacia Ab New gpr119modulators
JP2011524917A (ja) 2008-06-20 2011-09-08 メタボレックス， インコーポレイテッド アリールｇｐｒ１１９作動薬およびその使用
GB0812641D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812649D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
KR20110036609A (ko) 2008-07-10 2011-04-07 프로시디온 리미티드 피페리디닐 ｇｐｃｒ 작용제
EP2321308B9 (en) 2008-07-10 2012-08-08 Prosidion Limited Piperidine gpcr agonists
GB0812642D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
CA2730511C (en) 2008-07-11 2013-06-11 Robert Epple 4-phenoxymethylpiperidines as modulators of gpr119 activity
JP2011528365A (ja) 2008-07-16 2011-11-17 シェーリング コーポレイション Ｇｐｒ１１９モジュレーターとしての二環式ヘテロ環誘導体およびそれらの使用方法
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
US20110124652A1 (en) 2008-07-30 2011-05-26 Carpenter Andrew J Chemical Compounds and Uses
WO2010013849A1 (ja) 2008-08-01 2010-02-04 日本ケミファ株式会社 Ｇｐｒ１１９作動薬
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20100113480A1 (en) * 2008-10-30 2010-05-06 Michael Reuman Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists
WO2010059384A1 (en) * 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists
CA2747809A1 (en) 2008-12-23 2010-07-01 Joel M. Harris Bicyclic heterocycle derivatives and methods of use thereof
JP2012513469A (ja) 2008-12-23 2012-06-14 シェーリング コーポレイション ピリミジン誘導体及びその使用法
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
EP2379542B1 (en) 2008-12-24 2013-02-13 Cadila Healthcare Limited Novel oxime derivatives
WO2010074271A1 (ja) 2008-12-26 2010-07-01 武田薬品工業株式会社 糖尿病治療剤
JPWO2010084944A1 (ja) 2009-01-22 2012-07-19 田辺三菱製薬株式会社 新規ピロロ［２，３−ｄ］ピリミジン化合物
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US8410089B2 (en) * 2009-02-18 2013-04-02 Takeda Pharmaceutical Company Limited Fused heterocyclic ring compound
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
US20120095028A1 (en) 2009-03-20 2012-04-19 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
EP2414348B1 (en) 2009-04-03 2013-11-20 Merck Sharp & Dohme Corp. Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
JP2010265258A (ja) * 2009-04-15 2010-11-25 Daiichi Sankyo Co Ltd ピリミジルインドリン化合物を含有する医薬組成物
TW201039827A (en) * 2009-04-15 2010-11-16 Daiichi Sankyo Co Ltd Indoline compound
JP2012136439A (ja) 2009-04-24 2012-07-19 Nippon Chemiphar Co Ltd ジアザスピロアルカン誘導体
US20100285145A1 (en) * 2009-05-08 2010-11-11 Pfizer Inc Gpr 119 modulators
US20120052130A1 (en) * 2009-05-08 2012-03-01 Pfizer Inc. Gpr 119 modulators
JP2012526097A (ja) * 2009-05-08 2012-10-25 ファイザー・インク Ｇｐｒ１１９調節因子
WO2010135505A2 (en) 2009-05-20 2010-11-25 Janssen Pharmaceutica Nv Crystalline forms of 4-[6-(6-methanesulfonyl-2-methylpyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester
WO2010135506A1 (en) 2009-05-20 2010-11-25 Janssen Pharmaceutica Nv Process for the preparation of 4- [6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino) -5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester
GEP20135907B (en) 2009-06-05 2013-08-12 Pfizer L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators
AU2010264720A1 (en) 2009-06-24 2011-12-08 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
WO2010149685A1 (en) 2009-06-24 2010-12-29 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
EP2566864B1 (en) 2010-05-07 2014-09-03 Boehringer Ingelheim International GmbH Pyridazinones as gpr119 agonists
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
UY33805A (es) 2010-12-17 2012-07-31 Boehringer Ingelheim Int ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?.
WO2012098217A1 (en) 2011-01-21 2012-07-26 Boehringer Ingelheim International Gmbh Fused dihydrofurans as gpr119 modulators for the treatment of diabetes, obesity and related disorders
JP5935154B2 (ja) 2011-03-14 2016-06-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｐｒ１１９モジュレーターとしてのｎ−シクロプロピル−ｎ−ピペリジニルベンズアミド

Also Published As

Publication number Publication date
TW201113269A (en) 2011-04-16
US20110021491A1 (en) 2011-01-27
WO2010149685A1 (en) 2010-12-29
US8481731B2 (en) 2013-07-09
EP2445901A1 (en) 2012-05-02
JP2012530758A (ja) 2012-12-06

Similar Documents

Publication Publication Date Title
AR077214A1 (es) Heterociclos nitrogenados y composiciones farmaceuticas que los contienen
AR077215A1 (es) Derivados de piperidina, composiciones farmaceuticas y metodos relacionados con ellos
AR057071A1 (es) Producto de combinacion que comprende arilpirazoles sustituidos
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
AR075005A1 (es) Derivados de sulfonamida
PE20150230A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
AR086319A1 (es) Compuestos heterociclicos fusionados como moduladores de canal ionico
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
PE20140863A1 (es) Compuestos de benceno sustituidos con arilo o heteroarilo
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR051921A1 (es) Acidos sustituidos utiles como compuestos farmaceuticos para tratar trastornos respiratorios, composiciones farmaceuticas que los contienen, y procesos para su preparacion
CO6160227A2 (es) Pirazol amidas de acido carboxilico utiles como microbicidas
UY28823A1 (es) Compuestos de ácido alfa aril o heteroaril metil beta piperidino propanoico como antagonistas del receptor orl1
AR080074A1 (es) Naftiridinas sustituidas y su uso como medicamentos
AR075139A1 (es) Compuestos biciclicos para la reduccion de la produccion de beta-amiloide
AR078408A1 (es) Derivados de indol como moduladores de los crac
CL2008002654A1 (es) Compuestos derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, bloqueadores de los canales hcn; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cardiopatias isquemicas, insuficiencias cardiacas tanto sistolicas como diastolicas, entre otras.
AR079553A1 (es) Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros.
AR056892A1 (es) Derivados de cinolin-3-carboxamida, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion del receptor gabaa
ES2528441T3 (es) Hetarilaminonaftiridinas
AR064331A1 (es) Combinacion para tratar una infestacion parasitaria
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas
AR070345A1 (es) (dihidro ) pirrolo (2,1-a) isoquinolinas
AR077447A1 (es) Compuestos inhibidores de beta-secretasa, utiles para el tratamiento de enfermedades neurodegenerativas
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.

Legal Events

Date Code Title Description
FB Suspension of granting procedure